Bayer Wins FDA Priority Review and Analyst Upgrade as Turnaround Narrative Gains Credibility

Bayer has secured two regulatory accelerations from the US Food and Drug Administration in quick succession and a bullish analyst upgrade, signalling that the diversified group’s long-fought turnaround may be building tangible momentum — even as legal payouts continue to drain cash.

The FDA granted Priority Review status to Sevabertinib, Bayer’s experimental therapy for first-line treatment of HER2-mutated lung cancer, a designation that sharply shortens the approval timeline. Within 48 hours, the agency also accepted the company’s application for Asundexian, a FXIa inhibitor, for expedited review. Japan followed suit with a similar accelerated filing for the same drug. The twin milestones underscore a deliberate strategy to replenish the oncology pipeline before the patent cliffs on Xarelto and Eylea bite harder.

Deutsche Bank analyst Peter Spengler at DZ Bank upgraded Bayer shares from “Hold” to “Buy” on Tuesday, lifting the price target from €44 to €51 — a near-33% premium to the prior closing price of €38.45. The new target sits well above the current consensus estimate of approximately €48.58. Spengler cited the recently published first-quarter operational results and progress in the group’s restructuring efforts as the catalyst for his re-rating.

Q1 numbers paint a mixed picture

Bayer delivered a solid start to 2026. Group revenue rose 4.1% on a currency- and portfolio-adjusted basis to €13.4 billion, while adjusted EBITDA climbed 9.0% to €4.45 billion. Net profit more than doubled to €2.76 billion, helped in part by the sale of the antibiotic Avelox, which contributed around €250 million. Adjusted earnings per share reached €2.81 according to one source and €2.71 according to another — the discrepancy appears to be definitional, with the latter excluding the disposals gain. In either case, profitability improved markedly year-on-year.

Should investors sell immediately? Or is it worth buying Bayer?

The agricultural division posted a striking performance: segment EBITDA grew 17.9% despite a 15.1% decline in glyphosate herbicide sales, driven by strong seed volumes and the conclusion of a licensing dispute.

Yet the cash picture remains constrained. Free cash flow came in at minus €2.32 billion, compared with minus €1.53 billion in the year-ago period. Roughly €2 billion of that outflow was consumed by settlements in the PCB and glyphosate litigation complexes — a reminder that the company’s legal overhang continues to weigh on its financial flexibility.

Debt and dividends stay conservative

Bayer’s management is prioritising deleveraging over shareholder returns. The market expects a dividend of roughly €0.11 per share for 2026 — a symbolic payout that frees up capital for debt reduction and further settlement payments. Net financial debt remains elevated, and the DZ Bank upgrade acknowledges that sustained execution on both operations and litigation resolution is necessary to unlock the re-rating.

The stock currently trades around €38.49, just shy of its 50-day moving average but still more than 64% above the 52-week low of €23.41 struck in May 2025. It remains 22% below the February high of €49.17. Annualised volatility of 33% points to lingering uncertainty.

Bayer at a turning point? This analysis reveals what investors need to know now.

Strategy update on 27 May

On 27 May, Bayer’s management will present an update at the Deutsche Bank European Champions Conference in Frankfurt. Investors expect concrete details on the “Dynamic Shared Ownership” organisational model and a clearer roadmap for debt reduction. The event will test whether the growing analyst optimism — reflected in the DZ Bank upgrade — has operational substance behind it. A separate step was the agreement to acquire Perfuse Therapeutics for up to $2.45 billion, adding Phase II ophthalmology assets to the portfolio.

For now, the twin regulatory advances and the upgraded analyst call give Bayer a rare positive narrative. But the sheer size of the remaining legal liabilities — and the cash they consume — means the stock’s next leg higher ultimately depends on how quickly those legacy risks can be contained.

Ad

Bayer Stock: New Analysis - 20 May

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

en | DE000BAY0017 | BAYER | boerse | 69380375 |